Baseline Ex Vivo and Molecular Responses of Plasmodium falciparum Isolates to Piperaquine before Implementation of Dihydroartemisinin-Piperaquine in Senegal

Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of P. falciparum isolates collected in Dakar in 2013 to 2015 showed ex vivo-reduced susceptibility to piperaquine. Neithe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Robert, Marie Gladys, Foguim Tsombeng, Francis, Gendrot, Mathieu, Diawara, Silman, Madamet, Marylin, Kounta, Mame Bou, Wade, Khalifa Ababacar, Fall, Mansour, Gueye, Mamadou Wague, Benoit, Nicolas, Nakoulima, Aminata, Bercion, Raymond, Amalvict, Rémy, Fall, Bécaye, Wade, Boubacar, Diatta, Bakary, Pradines, Bruno
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2019
Soggetti:
Epidemiology and Surveillance
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496083/
https://ncbi.nlm.nih.gov/pubmed/30782997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02445-18
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi